38353-74-1

Usage

Chemical compound

2-[1-(Diphenylmethyl)azetidin-3-yl]-1H-isoindole-1,3(2H)-dione

Derivative of

Isoindole-1,3-dione

Contains

Azetidin-3-yl group and diphenylmethyl moiety

Potential pharmaceutical application

Studied for drug candidate for neurological disorders and cancer

Unique structure and properties

Promising candidate for further research and development in medicinal chemistry

Upstream product

• 33301-41-6 1-benzhydryl-3-azetidinyl methanesulfonate 
• 1074-82-4 potassium phtalimide 
• 14937-45-2 cetyltributylphosphonium bromide 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 

Downstream Products

• 40432-52-8 1-benzhydrylazetidin-3-ylamine 
• 102065-87-2 N-(1-benzhydryl-azetidin-3-yl)-acetamide 

Relevant academic research and scientific papers

Hydrogen Bonding Phase-Transfer Catalysis with Ionic Reactants: Enantioselective Synthesis of γ-Fluoroamines

Ammonium salts are used as phase-Transfer catalysts for fluorination with alkali metal fluorides. We now demonstrate that these organic salts, specifically azetidinium triflates, are suitable substrates for enantioselective ring opening with CsF and a chiral bis-urea catalyst. This process, which highlights the ability of hydrogen bonding phase-Transfer catalysts to couple two ionic reactants, affords enantioenriched γ-fluoroamines in high yields. Mechanistic studies underline the role of the catalyst for phase-Transfer, and computed transition state structures account for the enantioconvergence observed for mixtures of achiral azetidinium diastereomers. The N-substituents in the electrophile influence the reactivity, but the configuration at nitrogen is unimportant for the enantioselectivity.

Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof

The present invention relates to compounds of general formula [in-line-formulae]R—Z1—Z2—Z3—R1, ??(I)[/in-line-formulae] wherein R, R1 and Z1 to Z3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

3-aminoazetidine, its salts and intermediates of synthesis

The 3-aminoazetidine, its salts, new intermediates of formula STR1 wherein X' represents hydrogen or a protecting group and both X" represent hydrogen or, together with the nitrogen atom, a phthalimido group, X' not and both X" being hydrogen at the same